Views
8 years ago

Psicofarmacología 9

  • Text
  • Antipsicoticos
  • Bulimia
  • Panico
  • Depresion
  • Tratamiento
  • Pacientes
  • Anorexia
  • Psychiatry
  • Dosis
  • Benzodiazepinas
  • Antidepresivos
  • Trastornos
  • Trastorno
  • Ansiedad
  • Consideraciones
  • Adolescencia
Revista Latinoamericana de Psicofarmacología y Neurociencia.

Referencias

Referencias Bibliográficas 1. Ashton H: Benzodiazepine Withdrawal aoutcome in 50 patients. Br J Addiction 1987; 82: 665-671. 2. Charney D S, Heninger G R: Noradrenergic function and the machinsm ofa action of antianxiety treatment. I. The effect of log-term alprazolam treatment. Arch Gen psychiatry 1985; 42: 458-467. 3. charney D S, Woods S W, Goodman W K: Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986; 47: 580-586. 4. Chouinard G, Annable L, Fontaine R, Solyom L: Alprazolam in the treatment of generalized anxiety and panic disorder: a double-blind placebo-controlled study. Psychopharmacology 1982; 77: 229-233. 5. Dubovski S L: Generalized Anxiety Disorder: new concepts and psichopharmacologic therapies. J Clin Psychiatry 1990; 51 (suppl 1): 3-10. 6. Fyer A J, Liebowitz M R, Goran J M y cols: Discotinuation of alprazolam in panic patients. Am J Psychiatry 1987; 144: 303-308. 7. Herman J B, Rosembaum J F, Brotman A W: The Alprazolam to clonazepam switch for the treatment of panic disorder. J Clin Psychopharmacol 1987; 7: 175-178. 8. Hoehn-Saric R, Boekovec T, Neimaih J C:Generalized Anxiety Disorder. En: Treatments of Psychiatric Disorders. 2nd edition. Gabbard GO (Ed.) American Psychiatric Press, Washington, 1995; 1537-1567. 9. Hofmann S, Spiegel D: Panic Control Treatment and its applications. J Psychother Pract Res 1999; 8: 3-11. 10. Lecrubier Y, Judge R: Long term ealuation of paroxetine clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatrica Scand 1997; 95: 13-160. 11. Lydiard R B, Lesser I M, Ballenger J C y cols: Comparison study of alprazolam 2 mg, alprazolam 6 mg and placebo in panic disorder. J Clin Psychopharmacol 1992; 12: 96-103. 12. Marcowitz J S, Wiessman M M y cols; Quality of life in panic disorder. Arch Gen Psychiatry 1989; 46: 984- 992. 13. Mellman T A, Uhde T W: Withdrawal syndrome with gradual tapering of alprazolam. Am J Psychiatry 1989; 143: 1464-1466. 14. Michelson D, Lydiard R B y cols: Outcome assessment and clinical improvemente in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psichiatry 1998; 155: 1570-1577. 15. Nagy L M, Krystal J H, Woods S W, Xharney D S: Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. Arch Gen Psychiatry 1989; 46: 993-999. 16. Pecknold J C, Swinson R P, Kuch K, Lewis C P: Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III Discontinuation effects. Arch Gen Psichiatry 1988; 45: 429-436. 17. Pohl R B, Wolkow R M, Clary C M:Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psichiatry 1998; 155: 1189-1195. 18. Pollack M H, Tesar G E, Rosenbaum J F y cols: Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol 1986; 6: 302-304. 19. Rashid K, Patrisi G, Cook B: Multiple serious symptom formation with alprazolam. Presented at the Annual Meeting of the American Psychiatric Association, Montreal, Canada, 1988. 20. Rickels K, Case G, Downing R W y cols: Log.term diazepam therapy and clinica outcome. JAMA 1983; 250: 767-771.

21. Rickels K, Case G, DowninG R S y cols: Indications and contraindications for chornic anxiolytic treatment: is there tolreance to the anxiolytic effect? En: Kemali D, Racagni (eds). Chronic treatments in neuropsychiatry. Raven press, New York 1985; 193-204. 1985. 22. Rickels K, Fox I L, Greenblatt D J: Clorazepate and loraszepam: clinical improvement and rebound anxiety. Am J Psichiatry 1988; 145: 312-317. 23. Rickels K, Pollak M, Sheehan D y Haskins J T: Efficacy of extended release venlafaxin in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157: 968-974. 24. Rickels K, DeMartinis N, García-España F, Greemblatt D, Mandos L, Rynn M: Impramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term bezodiazepine therapy. Am J. Psichiatry 2000; 157: 1973-1979. 25. Roy-Byrne P P, Dager S R, Cowley D S, Vitaliano P, Dunner D L: Relapse and rebound following dincontinuation of benzodiazepine treatment of panic attacks: alprazolam versus diazepam. Am J Psychiatry 1989; 146: 860-865. 26. Roy-Burne PP, Ward N G, Donnelly P J: Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry 1989; 50: 44-48. 27. Schweizer E, Rickels K, Case W G y cols: Carbamazepine treatment in petients discontinuing benzodiazepine therapy: effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991; 48: 448-452. 28. Spiegel D, Bruce T: Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Am J Psychiatry 1997; 154: 773-781. 29. Uhlenhuth E H, Matuzas W, Glass R M y cols: Response of panic disorder to fixed dose alprazolam or imipramine. J Affect Disord 1989; 17: 261-270. 30. Winkinski S: Tratamiento a largo plazo del trastorno por pánico: historia natural, cronicidad y factores asociados. VERTEX, Rev Arg de Psiquiatría 1998; IX: 214-218.

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015